Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ropinirole, a non-ergoline dopamine agonist.

Wolfgang H Jost1, Dieter Angersbach

  • 1Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de

CNS Drug Reviews
|January 4, 2006
PubMed
Summary

Ropinirole, a non-ergoline dopamine agonist, effectively treats Parkinson's disease symptoms and improves mood. It offers an alternative to levodopa, potentially reducing long-term complications and showing neuroprotective effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

The German Parkinson expert meetings.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Editorial: Cognition in Parkinson's disease.

Frontiers in cognition·2026
Same author

Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Are We Heading into a Dead End, or Are We Treading Water?

Toxins·2026

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Dopamine agonists are crucial for Parkinson's disease (PD) management.
  • A wide array of available dopamine agonists complicates treatment selection for individual patients.

Purpose of the Study:

  • To review experimental and clinical studies on ropinirole for Parkinson's disease.
  • To evaluate ropinirole's efficacy in monotherapy and combination therapy.

Main Methods:

  • Review of published experimental and clinical studies on ropinirole.
  • Analysis of ropinirole's effects on motor and non-motor symptoms of Parkinson's disease.

Main Results:

  • Ropinirole effectively ameliorates bradykinesia, rigor, and tremor in Parkinson's disease.
  • It improves daily functioning and depressive moods in PD patients.

Related Experiment Videos

  • Ropinirole use avoids long-term levodopa complications and reduces associated problems, with potential neuroprotective benefits.

    • Conclusions:

    • Ropinirole is an effective non-ergoline dopamine agonist for Parkinson's disease treatment.
    • It offers benefits over levodopa, including reduced long-term complications.
    • Ropinirole is also effective for restless legs syndrome.